Plain-English translation of NCT04981145 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether iguratimod, a new treatment option, can help people with primary Sjögren's syndrome — a condition where the immune system damages the glands that produce tears and saliva. Researchers want to see if this medication can safely reduce symptoms like dry mouth and dry eyes, and improve overall health.
Primary Sjögren's syndrome can be very uncomfortable and affect quality of life, and current treatment options are limited. This trial exists to see if this medication might be a safer or more effective choice for people living with this condition.
You likely qualify if…
You likely don't qualify if…
You would take the study medication regularly at home, likely visiting the hospital or clinic multiple times to have your symptoms checked, blood work done, and to receive study medication refills. The trial is open-label, meaning you and your doctors will know you're receiving the medication. Your exact schedule and duration will be explained when you enroll, but plan for regular appointments to monitor how well the treatment is working and check for any side effects.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
China
Phase
Post-approval monitoring
Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Enrollment target
~78 participants
Started
January 2022
Primary completion
December 2024
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 70 Years
Last updated on clinicaltrials.gov in October 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Jing Xue
Sir Run Run Shaw Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.